Clinical Trial Update: A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase I study evaluated the safety, reactogenicity, and immunogenicity of the Sm-TSP-2 vaccine adsorbed to Alhydrogel, with or without the GLA-AF adjuvant, fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Schistosomiasis

Drugs mentioned

• Sm-TSP-2/Alhydrogel (Sm-TSP-2 vaccine with Alhydrogel adjuvant (with or without GLA-AF))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Schistosomiasis | Phase 1 | Status: COMPLETED